Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Aryloxypropanolamine targets amyloid aggregates and reverses Alzheimer-like phenotypes in Alzheimer mouse models.

Alzheimer's research & therapy - 29 Nov 2022

Lee Hee Yang, Yoon Soljee, Lee Jeong Hwa, Park Keunwan, Jung Youngeun, Cho Illhwan, Lee Donghee, Shin Jisu, Kim Kyeonghwan, Kim Sunmi, Kim Jimin, Kim Koeun, Han Seung Hoon, Kim Seong Muk, Kim Hye Ju, Kim Hye Yun, Kim Ikyon, Kim Young Soo

Abstract excerpt

BACKGROUND: Aggregated amyloid-β (Aβ) is considered a pathogenic initiator of Alzheimer's disease (AD), in strong association with tau hyperphosphorylation, neuroinflammation, synaptic dysfunction, and cognitive decline. As the removal of amyloid burden from AD patient brains by antibodies has shown therapeutic potential, the development of small molecule drugs inducing chemical dissociation and clearance of Aβ...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease
Share to Amyloid beta-Peptides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Amyloidogenic Proteins

Share to Amyloidosis

Share to Disease Models, Animal

Share to Mice, Transgenic

Share to Propanolamines

Source

Open in PubMed Open full text

Identifiers

PMID: 36443837
DOI: 10.1186/s13195-022-01112-6
PMCID: PMC9706920

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Aryloxypropanolamine targets amyloid aggregates and reverses Alzheimer-like phenotypes in Alzheimer mouse models.PMID 36443837Read ↗

Small-Molecule Amyloid Beta-Aggregation Inhibitors in Alzheimer's Disease Drug DevelopmentSemantic proximity Read ↗

An in vitro paradigm to assess potential anti-Aβ antibodies for Alzheimer’s diseaseSemantic proximity Read ↗

A Novel multifunctional 5,6-dimethoxy-indanone-chalcone-carbamate hybrids alleviates cognitive decline in Alzheimer’s disease by dual inhibition of acetylcholinesterase and inflammationSemantic proximity Read ↗

K114 inhibits A-beta aggregation and inflammation in vitro and in vivo in AD/Tg mice.Semantic proximity Read ↗

Aβ Oligomer Elimination Restores Cognition in Transgenic Alzheimer’s Mice with Full-blown PathologySemantic proximity Read ↗

The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson’s diseaseSemantic proximity Read ↗

The Anti-Amyloid-β and Neuroprotective Properties of a Novel Tricyclic Pyrone Molecule.Semantic proximity Read ↗

Imipramine and Olanzapine Block Apoe4-Catalyzed Polymerization of Aβ and Show Evidence of Improving Alzheimer’s Disease CognitionSemantic proximity Read ↗

Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer’s DiseaseSemantic proximity Read ↗

Soluble γ-secretase modulators selectively inhibit the production of the 42-amino acid amyloid β peptide variant and augment the production of multiple carboxy-truncated amyloid β species.Semantic proximity Read ↗

Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor.Semantic proximity Read ↗

Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.